All In Biotech

Drug Trial Radar · NCT05949593

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)

Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 429 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

429

Planned (sponsor's estimate)

Start

Jul 27, 2023

Primary completion

Jun 30, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Belite Bio, IncIndustry
Sponsor type
Industry
First posted
Jul 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.

Conditions

  • Geographic Atrophy

Interventions

  • TinlarebantDrug

    5 mg tablet taken orally once a day

  • PlaceboDrug

    Placebo tablets for tinlarebant 5 mg prepared similarly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To measure the rate of change (growth rate slope) in geographic atrophy (GA) lesion sizeTime frame: From baseline to Month 24]

Locations

49 sites in 8 countries. Site status is shown where the registry gives one.

  • Belite Study Site

    Phoenix, Arizona

  • Belite Study Site

    Arcadia, California

  • Belite Study Site

    Beverly Hills, California

  • Belite Study Site

    Huntington Beach, California

  • Belite Study Site

    Los Angeles, California

  • Belite Study Site

    Palo Alto, California

  • Belite Study Site

    San Diego, California

  • Belite Study Site

    Lakeland, Florida

  • Belite Study Site

    Hagerstown, Maryland

  • Belite Study Site

    Saint Louis Park, Minnesota

  • Belite Study Site

    Westbury, New York

  • Belite Study Site

    Cary, North Carolina

  • Belite Study Site

    Durham, North Carolina

  • Belite Study Site

    Wake Forest, North Carolina

  • Belite Study Site

    Portland, Oregon

  • Belite Study Site

    Philadelphia, Pennsylvania

  • Belite Study Site

    Sewickley, Pennsylvania

  • Belite Study Site

    Germantown, Tennessee

  • Belite Study Site

    Abilene, Texas

  • Belite Study Site

    Dallas, Texas

  • Belite Study Site

    San Antonio, Texas

  • Belite Study Site

    Warrenton, Virginia

  • Belite Study Site

    Chatswood, New South Wales, Australia

  • Belite Study Site

    Strathfield, New South Wales, Australia

  • Belite Study Site

    Brisbane, Queensland, Australia

  • Belite Study Site

    Adelaide, South Australia, Australia

  • Belite Study Site

    East Melbourne, Victoria, Australia

  • Belite Study Site

    Crawley, Western Australia, Australia

  • Belite Study Site

    Beijing, China

  • Belite Study Site

    Beijing, China

  • Belite Study Site

    Guandong, China

  • Belite Study Site

    Zhejiang, China

  • Belite Study Site

    Beijing, Beijing Municipality, China

  • Belite Study Site

    Chengdu, Sichuan, China

  • Belite Study Site

    Ostrava, Czechia

  • Belite Study Site

    Prague, Czechia

  • Belite Study Site

    Prague, Czechia

  • Belite Study Site

    Dijon, France

  • Belite Study Site

    Écully, France

  • Belite Study Site

    Lyon, France

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.